Cypherpunk Technologies Inc. (CYPH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cypherpunk Technologies Inc. (CYPH) Healthcare & Pipeline Overview

Cypherpunk Technologies Inc. is a clinical-stage biopharmaceutical company specializing in the acquisition and development of antibody therapies, primarily focused on its lead drug candidate, DKN-01, currently in clinical trials for treating esophagogastric, gynecologic, and colorectal cancers, positioning it within the competitive oncology therapeutics market.

What Is the Investment Thesis for CYPH?

Cypherpunk Technologies Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful clinical development and potential commercialization of DKN-01. Positive clinical trial results for DKN-01 in esophagogastric, gynecologic, and colorectal cancers could significantly increase the company's valuation. The partnership with BeiGene for development and commercialization in Asia, Australia, and New Zealand provides a potential revenue stream. However, the company's negative profit and gross margins (-8537.8% and -9631.6%, respectively) highlight the significant financial challenges and reliance on future clinical and commercial success. Investors should closely monitor clinical trial outcomes and partnership developments to assess the company's long-term viability.

Based on FMP financials and quantitative analysis

CYPH Key Highlights

Market capitalization of $127M, indicating a small-cap company with potential for high growth but also higher volatility.

• Negative profit margin of -8537.8%, reflecting the significant R&D expenses and lack of revenue from commercialized products.
• Negative gross margin of -9631.6%, highlighting the high cost of drug development and clinical trials.
• Beta of -0.22, suggesting the stock is less volatile than the overall market.
• No dividend yield, consistent with a growth-focused biopharmaceutical company reinvesting earnings into research and development.

Who Are CYPH's Competitors?

CYPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CYPH's Key Strengths?

Focus on innovative antibody therapies.

• Lead drug candidate in clinical trials.
• Strategic partnership with BeiGene.
• Experienced management team.

What Are CYPH's Weaknesses?

Limited financial resources.

• Dependence on the success of DKN-01.
• High R&D expenses.
• Negative profit and gross margins.

What Could Drive CYPH Stock Higher?

Data readouts from ongoing clinical trials of DKN-01 in esophagogastric, gynecologic, and colorectal cancers.

• Potential regulatory submissions for DKN-01 in key markets.
• Progress in the development of FL-501 and its advancement into clinical trials.
• New strategic partnerships and licensing agreements.

What Are the Key Risks for CYPH?

Negative return on equity (-46.9%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials for DKN-01 or FL-501.
• Regulatory delays or rejections.
• Competition from other companies developing similar therapies.
• Limited financial resources and dependence on future funding.
• Patent expirations and intellectual property challenges.

What Are the Growth Opportunities for CYPH?

• Expanding Clinical Trials for DKN-01: Cypherpunk Technologies Inc. can expand the clinical trials for DKN-01 to include additional cancer types and combination therapies. The global oncology market is projected to reach $286.6 billion by 2028, offering significant potential for DKN-01 if it demonstrates efficacy across a broader range of cancers. This expansion could occur over the next 3-5 years, contingent on positive trial results and regulatory approvals. A competitive advantage lies in DKN-01's novel mechanism of action targeting DKK1.
• Advancing FL-501 into Clinical Development: Progressing FL-501, a monoclonal antibody inhibiting GDF-15 protein, from preclinical to clinical trials represents another growth opportunity. GDF-15 is implicated in various diseases, including cancer and metabolic disorders. The market for GDF-15 targeted therapies is nascent but promising, with potential applications in cachexia and other conditions. Clinical trials could commence within the next 2-3 years, depending on preclinical data and funding. This provides diversification beyond DKN-01.
• Strategic Partnerships and Licensing Agreements: Forming additional strategic partnerships and licensing agreements, similar to the BeiGene collaboration, can accelerate the development and commercialization of Cypherpunk Technologies' drug candidates. These partnerships can provide financial resources, expertise, and access to new markets. Focus could be on securing partnerships for specific geographic regions or therapeutic areas. These agreements could be established within the next 1-2 years, enhancing the company's global reach and development capabilities.
• Acquisition of Complementary Technologies or Assets: Cypherpunk Technologies Inc. could pursue the acquisition of complementary technologies or assets to expand its pipeline and capabilities. This could include acquiring companies with promising preclinical or clinical-stage assets in oncology or related therapeutic areas. The timeline for acquisitions is variable, depending on market conditions and available opportunities. A successful acquisition could diversify the company's portfolio and reduce reliance on DKN-01.
• Securing Regulatory Approvals and Commercializing DKN-01: Obtaining regulatory approvals for DKN-01 in key markets, such as the United States and Europe, is crucial for commercial success. The timeline for regulatory approvals depends on the clinical trial results and regulatory review processes. Successful commercialization of DKN-01 could generate significant revenue and establish Cypherpunk Technologies Inc. as a player in the oncology therapeutics market. This represents the most significant value driver for the company.

What Threats Does CYPH Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from established pharmaceutical companies.
• Patent expirations.

What Are CYPH's Competitive Advantages?

• Proprietary antibody therapies with patent protection.
• Clinical data demonstrating efficacy and safety.
• Strategic partnerships with established pharmaceutical companies.
• Expertise in antibody development and oncology.

What Does CYPH Do?

Cypherpunk Technologies Inc., formerly known as Leap Therapeutics, Inc., is a biopharmaceutical company dedicated to acquiring and developing innovative antibody therapies for the treatment of cancer. Incorporated in 2011 and based in Cambridge, Massachusetts, the company's primary focus is on advancing its lead clinical-stage drug candidate, DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKN-01 is currently undergoing several clinical trials targeting esophagogastric, gynecologic cancers, and colorectal cancer. In addition to DKN-01, Cypherpunk Technologies is also developing FL-501, a monoclonal antibody that inhibits GDF-15 protein, which is in preclinical development. The company has strategic agreements, including an option and license agreement with Adimab, LLC and BeiGene, Ltd., to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The name change to Cypherpunk Technologies Inc. in November 2025 reflects the company's evolution and strategic direction within the biopharmaceutical landscape.

What Products and Services Does CYPH Offer?

• Acquires and develops antibody therapies for cancer treatment.
• Focuses on inhibiting key proteins involved in cancer progression.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Collaborates with other companies to develop and commercialize its therapies.
• Develops monoclonal antibodies to target specific cancer-related proteins.
• Seeks regulatory approvals for its drug candidates in various markets.
• Aims to improve outcomes for patients with cancer through innovative therapies.

How Does CYPH Make Money?

• Develops and patents novel antibody therapies for cancer.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments, royalties, and potential direct sales.
• Focuses on early-stage drug development and clinical trials.

What Industry Does CYPH Operate In?

Cypherpunk Technologies Inc. operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and regulatory hurdles. The oncology therapeutics market is a significant segment within the biotechnology industry, driven by the increasing prevalence of cancer globally. The company's focus on antibody therapies aligns with the growing trend towards targeted therapies in cancer treatment. Competition includes established pharmaceutical companies and other biotechnology firms developing similar therapies. Success depends on demonstrating clinical efficacy, securing regulatory approvals, and establishing commercial partnerships.

Who Are CYPH's Key Customers?

• Patients with cancer who may benefit from its therapies.
• Healthcare providers who prescribe and administer its drugs.
• Pharmaceutical companies that partner for commercialization.
• Research institutions involved in clinical trials.

Company Profile

Cypherpunk Technologies Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Douglas E. Onsi. CYPH has traded publicly since 2017.

Cypherpunk Technologies Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 13.93 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Cypherpunk Technologies Inc. stands at -46.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -65.1%, showing how much profit it generates from its asset base. A current ratio of 27.28 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -55.3%, the inverse of the P/E and a quick read on earnings relative to price.

CYPH Valuation & Market Position

With a $127M market cap, Cypherpunk Technologies Inc. sits in the micro-cap segment of the market. Relative to its peer group, CYPH's quantitative score of 41/100 is below the peer average of 76/100.

Cypherpunk Technologies Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 67.3% below estimates on average.

Wall Street analysts project Cypherpunk Technologies Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.51.

CYPH Financials

CYPH Latest News

CYPH Analyst Consensus

CYPH MoonshotScore

Common Questions About CYPH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources